How to Administer Remicade (Infliximab) via IV Infusion
Infliximab must be administered as an intravenous infusion over at least 2 hours using an in-line sterile, non-pyrogenic, low-protein-binding filter (pore size ≤1.2 µm), with appropriate personnel and emergency medications immediately available to manage infusion reactions. 1
Dosing Protocol
Standard Induction Dosing
- 5 mg/kg administered at weeks 0,2, and 6 2, 3, 1
- For psoriasis and inflammatory bowel disease, this is the established induction regimen
Maintenance Dosing
- 5 mg/kg every 8 weeks after completing induction 2, 1
- Dose escalation to 10 mg/kg or shortening intervals to every 4 weeks may be necessary for patients losing response 2, 3
- For Crohn's disease specifically, combination therapy with thiopurines is recommended for at least 6-12 months to reduce immunogenicity 4
Reconstitution and Preparation
Step-by-Step Preparation (per FDA label) 1:
Calculate dose: Determine total volume needed based on patient weight (5 mg/kg)
Reconstitute each 100 mg vial:
- Add 10 mL Sterile Water for Injection using ≤21-gauge needle
- Direct stream to glass wall of vial (not directly onto powder)
- Gently swirl to dissolve—DO NOT SHAKE
- Allow to stand 5 minutes
- Solution should be colorless to light yellow and opalescent
Dilute to 250 mL:
- Use only 0.9% Sodium Chloride (no other diluent)
- Remove volume from 250 mL NS bag equal to reconstituted infliximab volume
- Add reconstituted infliximab to NS bag
- Final concentration: 0.4-4 mg/mL
- Must begin infusion within 3 hours of reconstitution 1
Infusion Administration
Infusion Rate and Duration
- Standard: 2-hour infusion minimum 5, 1
- Must use in-line filter (≤1.2 µm pore size) 1
- Accelerated infusions (1 hour for maintenance, 30 minutes for subsequent doses) are safe in patients without prior infusion reactions 6, 7, 8, though not FDA-approved
Critical Safety Requirements
- Ensure resuscitation equipment and medications available before starting 1
- Monitor patient during and for period after infusion
- Do not infuse concomitantly with other agents in same IV line 1
Premedication Considerations
Routine premedication is NOT required 9, 1. The evidence shows:
- Premedication with antihistamines, acetaminophen, or corticosteroids may be used but is not routinely indicated 9, 1
- Studies demonstrate no significant reduction in infusion reactions with routine premedication 10, 11
- Diphenhydramine may actually increase infusion reaction rates 8
- Reserve premedication for patients with prior mild-moderate infusion reactions 1
Managing Infusion Reactions
Mild to Moderate Reactions 5, 1:
- Slow or temporarily stop infusion
- Administer symptomatic treatment (antihistamines, hydrocortisone, acetaminophen)
- May reinitiate at lower rate once symptoms resolve
- Discontinue if reactions recur
Severe Reactions 5, 1:
- Immediately discontinue infusion
- Infliximab is contraindicated for future use
- Does not preclude use of other anti-TNF agents 5
Infusion reactions occur in approximately 20% of patients, typically within first 1-2 hours, with most being mild 5. Risk is highest during first 8 infusions 7.
Baseline and Ongoing Monitoring
Before Starting Infliximab 3, 1:
- Tuberculosis screening mandatory: PPD or interferon-gamma release assay plus chest X-ray
- Complete blood count (CBC)
- Liver function tests (LFT)
- Hepatitis B and C screening
During Therapy 3:
- Periodic history and physical examination
- Consider yearly PPD testing
- Periodic CBC and LFT monitoring
Key Contraindications and Warnings
- Contraindicated: Doses >5 mg/kg in moderate-severe heart failure (NYHA Class III/IV) 3, 1
- Contraindicated: Previous severe hypersensitivity to infliximab or murine proteins 1
- Do not initiate with active infection 1
- Increased risk of serious infections including tuberculosis reactivation 1
Cost and Efficiency Considerations
Accelerated infusions (1 hour for maintenance) reduce costs by approximately 37% compared to standard 2-hour infusions, primarily through reduced nursing time and patient productivity loss, without compromising safety 8. However, this remains off-label and should only be implemented after tolerance to standard infusions is established 6, 7.